article

Hit-to-lead discovery at a nonprofit research institute

Posted: 7 February 2019 | | No comments yet

Small molecule drug discovery has long been the domain of pharmaceutical companies, and that’s not likely to change anytime soon. But there’s a cadre of universities and nonprofit research institutes that have embraced drug development at its earliest stages, in some cases identifying and optimising compounds that target possible disease-driving proteins discovered in their labs.

    To read this article in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


    *


    *


    *


    *


    *


    *


    *


    *

    Leave a Reply

    Your email address will not be published. Required fields are marked *